---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-151845"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2023-05-23T23:59:59+00:00"
generated_at: "2026-06-14T17:03:42.369943+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Alnylam shareholders re-elect four Class I directors, approve say-on-pay, ratify auditor

## Summary
- Michael Bonney re-elected with 101.9M for vs 11.8M against; Yvonne Greenstreet 112.4M for vs 1.3M against.
- Phillip Sharp re-elected 101.4M for vs 12.3M against; Elliott Sigal 110.1M for vs 3.6M against.
- Say-on-pay approved: 109.7M for, 4.0M against; 1-year frequency recommended with 113.5M votes.
- PricewaterhouseCoopers ratified as independent auditor for FY2023: 116.1M for, 1.8M against.

## SEC filing metadata
- accession: 0001193125-23-151845
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2023-05-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000119312523151845/0001193125-23-151845-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000119312523151845/d689062d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-151845
- JSON: https://secwatch.observer/filing/0001193125-23-151845.json
- Plain text: https://secwatch.observer/filing/0001193125-23-151845.txt

## Key facts
- Shareholder Votes
  ALNYLAM PHARMACEUTICALS, INC. shareholders approved Advisory vote on named executive officer compensation at the 2023-05-18 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-05-18
  source text: The Company’s stockholders approved, in a non-binding advisory vote, the compensation of the Company’s named executive officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000119312523151845/0001193125-23-151845-index.htm
- Shareholder Votes
  ALNYLAM PHARMACEUTICALS, INC. shareholders approved Advisory vote on frequency of future advisory votes on named executive officer compensation at the 2023-05-18 meeting.
  - Proposal: say on pay frequency
  - Outcome: passed
  - Meeting: 2023-05-18
  source text: The Company’s stockholders recommended, in a non-binding advisory vote, a frequency of every One Year for future advisory stockholder votes on the compensation of the Company’s named executive officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000119312523151845/0001193125-23-151845-index.htm
- Shareholder Votes
  ALNYLAM PHARMACEUTICALS, INC. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent auditors at the 2023-05-18 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-18
  source text: The Company’s stockholders ratified the appointment by the Company’s Board of Directors of PricewaterhouseCoopers LLP as the Company’s independent auditors for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000119312523151845/0001193125-23-151845-index.htm
- Shareholder Votes
  ALNYLAM PHARMACEUTICALS, INC. shareholders approved Election of Class I Directors at the 2023-05-18 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-05-18
  source text: The Company’s stockholders re-elected the four persons listed below as Class I directors, each to serve until the Company’s 2026 annual meeting of stockholders or until his or her successor is duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000119312523151845/0001193125-23-151845-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.